A Prospective, Controlled, Double Blind, Single Center, Randomized, 3 Arm, Phase 1b/2a Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 Delivered as an Intranasal Spray in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

Trial Profile

A Prospective, Controlled, Double Blind, Single Center, Randomized, 3 Arm, Phase 1b/2a Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 Delivered as an Intranasal Spray in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs B 244 (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions
  • Sponsors AOBiome
  • Most Recent Events

    • 19 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
    • 19 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
    • 21 Mar 2018 According to an AOBiome media release, company has announced clinical findings from Part 1, and has initiated Part 2 of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top